Abstract:Abstract To date, dysregulation of more than 450 RNA-binding proteins (RBPs) across a multitude of cancers has been implicated in tumorigenesis and chemoresistance. In fact, emerging evidence suggests RBPs are principal modulators of every hallmark of cancer progression. Functionally, RBPs are believed to modulate the stability, localization, and translation of transcripts encoding for virtually all known oncogenes and tumor suppressor genes. Consequently, aberrant expression of RBPs may contribute to the malignant transformation of cancer cells through enhancing the expression of oncogenes or decreasing the expression of tumors suppressor genes, such as TP53. As a potent transcription factor, TP53 is a leading regulator of numerous signaling pathways involved in tumor suppression. While mutation or deletion of TP53 contributes to tumorigenesis in more than half of all human cancers, suppression of wild-type TP53 expression also drives tumorigenesis. Thus far, multiple RBPs have been implicated in the repression of wild-type TP53, such as RNA-binding motif protein 38 (RBM38). Specifically, RBM38 interacts with eukaryotic translation initiation factor 4E (EIF4E) on the TP53 transcript, preventing EIF4E from binding to TP53 m7G cap, thus inhibiting TP53 translation. We previously demonstrated that Pep8, an 8 amino acid peptide derived from RBM38, disrupts the RBM38-EIF4E complex enhancing TP53 expression. Moreover, Pep8 alone or in combination with doxorubicin, significantly decreased tumor xenograft growth. As activation of wild-type TP53 by targeting non-genetic mechanisms that inhibit TP53 expression is a promising therapeutic tactic for malignancies that carry wild-type TP53, we are developing more efficacious Pep8 derivatives as a novel therapeutic approach for cancers that express wild-type TP53. Citation Format: Chris August Lucchesi, Jin Zhang, Xinbin Chen. Targeting the RBM38-EIF4E complex to increase wild-type p53 as a novel cancer therapeutic strategy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1037.

Structural Basis for Translational Inhibition by the Tumour Suppressor Pdcd4

Human tumor suppressor protein Pdcd4 binds at the mRNA entry channel in 40S small ribosomal subunit

Human tumor suppressor protein Pdcd4 binds at the mRNA entry channel in the 40S small ribosomal subunit

The Impact of Pdcd4, a Translation Inhibitor, on Drug Resistance

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

Role of Programmed Cell Death 4 in Diseases: a Double-Edged Sword

Human tumor suppressor PDCD4 directly interacts with ribosomes to repress translation

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

Programmed Cell Death 4 Modulates Lysosomal Function by Inhibiting TFEB Translation.

Structural Basis of Dcp2 Recognition and Activation by Dcp1

Role of PDCD4 in Inflammation and Tumors: a Double-Edged Sword

Dissecting the Roles of PDCD4 in Breast Cancer

Crystal Structure of Dcp1p and Its Functional Implications in Mrna Decapping

The Tumor Suppressive Role of eIF3f and Its Function in Translation Inhibition and rRNA Degradation

Crystal Structure and Functional Analysis of DEAD-box Protein Dhh1p.

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

Structure and Function of Translationally Controlled Tumor Protein

PDCD4 Triggers Α-Synuclein Accumulation and Motor Deficits Via Co-Suppressing TFE3 and TFEB Translation in a Model of Parkinson’s Disease

A cyclin-dependent kinase, CDK11/p58, represses cap-dependent translation during mitosis

Conjunction of Potential G-quadruplex and Adjacent Cis-Elements in the 5' UTR of Hepatocyte Nuclear Factor 4-Alpha Strongly Inhibit Protein Expression.